Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Radiopharmaceutical CDMO Market Size/Share Worth USD 7.2 Billion by 2034 at a 9.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Radiopharmaceutical CDMO Market Size, Trends and Insights By Application...
October 18, 2025 03:00 ET | Source: AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer...
October 17, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its...
October 16, 2025 06:52 ET | Source: Research and Markets

Nuclear Medicine Equipment Market Analysis Report 2025-2035

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Equipment Market - A Global and Regional Analysis: Focus on Application, End User, Country, and Region - Analysis and Forecast,...
October 16, 2025 02:00 ET | Source: AdvanCell

AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors

Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a...
October 12, 2025 18:05 ET | Source: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
September 29, 2025 07:00 ET | Source: AdvanCell

AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25

Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six...
September 04, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual...
August 19, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and...
July 10, 2025 05:10 ET | Source: Angelini Ventures

Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

- Regina Hodits, Managing Director to join NUCLIDIUM’s Board of Directors Rome, Italy, 10th July 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in...